← Back
Data updated: Jun 28, 2026
KALEO INC
Pharma Pharmaceuticals
KALEO INC is a pharmaceutical company with 4 FDA-approved products.
2012
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
KALEO INC's Key Drugs
KALEO INC's core commercial portfolio centers on AUVI-Q — its most strategically important drugs approved in the last 15 years.
KALEO INC's Recent FDA Approvals
New NDA/BLA approvals for KALEO INC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
KALEO INC's Therapeutic Areas
Disease areas where KALEO INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
KALEO INC Pipeline Snapshot
Active clinical trials for KALEO INC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AUVI-Q leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (3)
Company Info
- First Approval
- 2012-08-10
- Latest
- 2025-04-30
- Applications
- 4